What are the stages of tissue repair?

Inflammation, then proliferation, then remodelling. The inflammatory phase clears and secures the site, proliferation builds new tissue, and remodelling refines it over months into something closer to the original architecture.

Why are BPC-157 and TB-500 studied together?

Because they act at different points in the repair sequence. BPC-157 is studied for new blood vessel formation and TB-500 for cell migration, and acting on one does little if the other is the limiting step.

Which of these has the strongest evidence?

GHK-Cu, by a clear margin. It has decades of human clinical research behind it, mostly from dermatology. BPC-157 research is overwhelmingly preclinical rodent work, and TB-500 has a smaller literature again.

Is inflammation something to be suppressed during healing?

Not entirely. The inflammatory phase is a necessary part of repair — it clears and secures the site. The research interest is in resolving it cleanly and moving on, rather than eliminating it, since inflammation that lingers causes secondary damage and scarring.

Are any of these approved for therapeutic use?

No. These are research-grade compounds and are not approved by the TGA for human or veterinary use.

Research Library›Recovery & Tissue Repair›Tissue Repair Peptides Explained

Category Overview

Tissue Repair Peptides Explained: Healing Happens in Stages

Repair is not one process but a sequence, and the compounds in this category act at different points in it. That is why they are studied together rather than as alternatives.

8 min read·4 studies cited·Updated July 2026

Quick Reference

Category	Tissue repair and recovery
Key principle	Repair runs in phases, not all at once
Compounds covered	BPC-157, TB-500, GHK-Cu, KPV, ARA-290 and others
Common pairing	BPC-157 with TB-500
Status	Research use only

Repair Runs in Stages

Tissue repair is not a single event. It unfolds in a sequence — inflammation, then proliferation, then remodelling — and each stage has to finish before the next works properly. Understanding this explains almost everything about how this category is organised.

The sequence, in plain language: think of repairing a damaged building. First the site is cleared and secured, and the emergency crews arrive — that is the inflammatory phase, and it is necessary rather than unwanted. Then materials are delivered and new structure goes up: proliferation. Then, over months, the rough work is refined into something that matches the original — remodelling. Rush the first stage and you build on rubble. Skip the last and you are left with something structurally sound but crude, which in tissue means scar rather than proper architecture.

The compounds here are studied at different points in that sequence, which is why the research pairs them rather than choosing between them.

Which Compound Sits Where

BPC-157 is studied for angiogenesis — the formation of new blood vessels around an injury. Nothing else in the sequence proceeds properly without blood supply, which is why it tends to be discussed first.

TB-500 binds actin, the protein forming the internal scaffolding that lets cells move. Its research concerns cell migration — getting repair cells to the site at all.

GHK-Cu is studied at the remodelling end, where collagen and the extracellular matrix are laid down and refined. It has the deepest human literature of the group, largely from dermatology.

KPV works on the inflammatory side, inhibiting NF-κB — a master regulator of inflammation — and is studied particularly in gut tissue.

ARA-290 comes at repair from an entirely different angle, targeting a tissue-protective receptor derived from erythropoietin signalling.

Why They Are Studied Together

Because acting on one stage does little if another is the limiting factor. New blood vessels are of no use if repair cells cannot migrate to the site; migration achieves little if the matrix is never properly remodelled.

This is the reasoning behind the BPC-157 and TB-500 pairing, which is the most studied combination in this category, and behind adding GHK-Cu for the remodelling phase.

It is worth being clear about the evidence: BPC-157 research is overwhelmingly preclinical, largely rodent work from the University of Zagreb. TB-500 has some equine veterinary literature alongside cell-level work on its parent molecule. GHK-Cu is the outlier, with decades of human dermatological research behind it.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current pharmaceutical design, 2011. PubMed
Malinda KM, Sidhu GS, Mani H, et al. “Thymosin beta4 accelerates wound healing.” The Journal of investigative dermatology, 1999. PubMed
Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International journal of molecular sciences, 2018. PubMed
Gurtner GC, Werner S, Barrandon Y, et al. “Wound repair and regeneration.” Nature, 2008. PubMed